German Rxing levels too high, says study

18 October 2001

Too many drugs are being prescribed in Germany, and about 20% of thehealth funds' current drug spending could be eliminated, says a report by Ulrich Schwabe of the Pharmacological Institute at Heidelberg University and Dietrich Paffrath.

They estimate savings of $8.1 billion Deutschemarks ($3.76 billion) annually, and say the latest government announcement of its plan to increase the drug spending budget overall has actually made the situation worse.

In 2000, drug spending rose 2.8% to 37.8 billion marks, with generics' share growing and with fewer products of dubious therapeutic value prescribed, the report says. This rise, albeit moderate, is put down to doctors prescribing more innovative new drugs, although overall, they were less eager to reach for their prescribing pads.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight